- Home
- ONDS vs BLRX Comparison
ONDS vs BLRX Comparison
Compare ONDS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONDS | BLRX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 12.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ONDS | BLRX |
|---|---|---|
| Price | $12.23 | $2.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $11.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 82.0M | 27.2K |
| Earning Date | 11-13-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,748,922.00 | $12,735,000.00 |
| Revenue This Year | $417.68 | N/A |
| Revenue Next Year | $244.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 208.40 | N/A |
| 52 Week Low | $0.57 | $2.30 |
| 52 Week High | $12.93 | $7.77 |
Technical Indicators
Market Signals| Indicator | ONDS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.43 | 45.81 |
| Support Level | $8.21 | $2.71 |
| Resistance Level | $9.84 | $2.99 |
| Average True Range (ATR) | 0.95 | 0.19 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 86.24 | 69.23 |
Price Performance
Historical ComparisonAbout ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.